Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment.
1. How are personalised strategies impacting the treatment of melanoma? (0:11)
2. What molecular markers have been validated to inform selection of therapy? (1:04)
3. What is the main focus of current research investigating combinations of therapy in melanoma? (2:16)
4. What have been the latest advances in systemic adjuvant treatment of stage II/III melanoma? (4:20)
5. What do you see as the most important advance in melanoma treatment in recent years? (5:35)
Speaker disclosures: Paolo Ascierto has provided an advisory role for BMS, Roche, MSD, Array, Novartis, Amgen, EMD Serono, Pierre-Fabre, Incyte, Genmad, New Link Genetics, Medimmune, AstraZeneca and Sindax. He has also received research funds from BMS, Roche and Array.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Melanoma
Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]
Georgina Long, ESMO 2022: CheckMate 915 study – The use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma
In patients with resectable melanoma, circulating tumor DNA (ctDNA) detection post-resection may be useful to inform disease state and recurrence risk. Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss CheckMate 915 study and what it taught us about the use of nivolumab plus ipilumab in the adjuvant treatment of melanoma, and […]
Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial
touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Questions 1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!